R. Mishra, M. Barman, Monika Singh, S. Snigdha, B. Bhardwaj, P. Saxena, Smriti Sahu
{"title":"离子交换树脂法制备盐酸左西曲嗪掩口溶片及评价","authors":"R. Mishra, M. Barman, Monika Singh, S. Snigdha, B. Bhardwaj, P. Saxena, Smriti Sahu","doi":"10.21276/IJRDPL.2278-0238.2018.7(5).3104-3109","DOIUrl":null,"url":null,"abstract":"http://dx.doi.org/10.21276/IJRDPL.22780238.2018.7(5).3104-3109 ABSTRACT: Levocetirizine dihydrochloride is a third-generation non-sedating antihistamine drug derived from the second generation anti-histamine cetrizine. It is H1receptorantagonist.Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation mediated by immunoglobulinE (IgE) in the membrane lining the nose after allergen exposure. Thus, formulating Levocetirizine into an orodispersible dosage form would provide fast relief. The Levocetirizine is bitter in taste so the Kyron T-134 (ion exchange resin synthetic which is inert organic polymers consist of hydrocarbon network to which ionizable groups are attached and they have the ability to exchange their labile ions for ions present in the solution with which they are in contact) was used to mask the taste and to formulate Mouth dissolving tablets using drug resin complex. The tablets were evaluated for the drug content, weight variation, water absorption ratio, wetting time, invitro disintegration, hardness, friability, thickness. All the parameters were found to be acceptable in range. The optimized formulation was disintegrated in 25 seconds and complete drug was released from tablet in10 minutes. It has been compared with marketed formulation and the drug release rate was found to be enhanced. Thus, results showed that Levocetirizine dihydrochloride was successfully formulated into Mouth Dissolving Tablets.","PeriodicalId":14211,"journal":{"name":"International Journal of Research and Development in Pharmacy & Life Sciences","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Formulation and evaluation of Taste Masked Mouth Dissolving Tablet of Levocetrizine dihydrochloride by using Ion-Exchange Resin\",\"authors\":\"R. Mishra, M. Barman, Monika Singh, S. Snigdha, B. Bhardwaj, P. Saxena, Smriti Sahu\",\"doi\":\"10.21276/IJRDPL.2278-0238.2018.7(5).3104-3109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"http://dx.doi.org/10.21276/IJRDPL.22780238.2018.7(5).3104-3109 ABSTRACT: Levocetirizine dihydrochloride is a third-generation non-sedating antihistamine drug derived from the second generation anti-histamine cetrizine. It is H1receptorantagonist.Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation mediated by immunoglobulinE (IgE) in the membrane lining the nose after allergen exposure. Thus, formulating Levocetirizine into an orodispersible dosage form would provide fast relief. The Levocetirizine is bitter in taste so the Kyron T-134 (ion exchange resin synthetic which is inert organic polymers consist of hydrocarbon network to which ionizable groups are attached and they have the ability to exchange their labile ions for ions present in the solution with which they are in contact) was used to mask the taste and to formulate Mouth dissolving tablets using drug resin complex. The tablets were evaluated for the drug content, weight variation, water absorption ratio, wetting time, invitro disintegration, hardness, friability, thickness. All the parameters were found to be acceptable in range. The optimized formulation was disintegrated in 25 seconds and complete drug was released from tablet in10 minutes. It has been compared with marketed formulation and the drug release rate was found to be enhanced. Thus, results showed that Levocetirizine dihydrochloride was successfully formulated into Mouth Dissolving Tablets.\",\"PeriodicalId\":14211,\"journal\":{\"name\":\"International Journal of Research and Development in Pharmacy & Life Sciences\",\"volume\":\"3 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Research and Development in Pharmacy & Life Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21276/IJRDPL.2278-0238.2018.7(5).3104-3109\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Research and Development in Pharmacy & Life Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21276/IJRDPL.2278-0238.2018.7(5).3104-3109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Formulation and evaluation of Taste Masked Mouth Dissolving Tablet of Levocetrizine dihydrochloride by using Ion-Exchange Resin
http://dx.doi.org/10.21276/IJRDPL.22780238.2018.7(5).3104-3109 ABSTRACT: Levocetirizine dihydrochloride is a third-generation non-sedating antihistamine drug derived from the second generation anti-histamine cetrizine. It is H1receptorantagonist.Allergic rhinitis is a symptomatic disorder of the nose induced by inflammation mediated by immunoglobulinE (IgE) in the membrane lining the nose after allergen exposure. Thus, formulating Levocetirizine into an orodispersible dosage form would provide fast relief. The Levocetirizine is bitter in taste so the Kyron T-134 (ion exchange resin synthetic which is inert organic polymers consist of hydrocarbon network to which ionizable groups are attached and they have the ability to exchange their labile ions for ions present in the solution with which they are in contact) was used to mask the taste and to formulate Mouth dissolving tablets using drug resin complex. The tablets were evaluated for the drug content, weight variation, water absorption ratio, wetting time, invitro disintegration, hardness, friability, thickness. All the parameters were found to be acceptable in range. The optimized formulation was disintegrated in 25 seconds and complete drug was released from tablet in10 minutes. It has been compared with marketed formulation and the drug release rate was found to be enhanced. Thus, results showed that Levocetirizine dihydrochloride was successfully formulated into Mouth Dissolving Tablets.